Does neurotropin-3 have a therapeutic implication in major depression?

Chi Un Pae, David M. Marks, Changsu Han, Ashwin A. Patkar, David Steffens

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Although several classes of antidepressants are used to treat major depression, there is an unmet need in real clinical practice because not all patients treated with an antidepressant fully recover from their functional impairment. Hence, the development of new antidepressants based on a novel therapeutic mechanism may help in the development of more effective and ideal antidepressive agents. There is emerging evidence suggesting that the etiopathogenesis of depression involves transmitters other than the major neurotransmitters such as serotonin, norepinephrine, and dopamine. Therefore, it has consistently been suggested that an alteration in neuroprotection and synaptic plasticity is associated with the pathogenesis and therapeutic mechanism of depression. Neurotropin-3 (NT3) is an interesting protein that regulates neuronal survival, synaptic plasticity, and neurotransmission. It is widely expressed in the hippocampus and facilitates hippocampal plasticity by regulating neurogenesis. It has been also reported that an infusion of NT3 increases the level of brain-derived neurotrophic factor (BDNF) mRNA expression in the cerebral cortex and produces BDNF-like effects that induce cortical tyrosine kinase B phosphorylation. BDNF has been consistently implicated in the pathogenesis of depression and the therapeutic mechanism of antidepressants. It has also been implicated in the treatment effect of mood stabilizers such as lithium. NT3 has demonstrated its possible antidepressant effect in a learned helpless animal model. Animal studies have shown that it also modulates the neurotransmitters, serotonin and noradrenaline, which are essential in the development and treatment of depression. Therefore, further studies on the therapeutic implications of NT3 for depression are warranted and are expected for the development of newer, effective antidepressants.

Original languageEnglish
Pages (from-to)1515-1522
Number of pages8
JournalInternational Journal of Neuroscience
Volume118
Issue number11
DOIs
Publication statusPublished - 2008 Nov 1

Fingerprint

Antidepressive Agents
Depression
Brain-Derived Neurotrophic Factor
Neuronal Plasticity
Therapeutics
Neurotransmitter Agents
Serotonin
Norepinephrine
Neurogenesis
neurotropin
Lithium
Synaptic Transmission
Cerebral Cortex
Protein-Tyrosine Kinases
Hippocampus
Dopamine
Animal Models
Phosphorylation
Messenger RNA
Proteins

Keywords

  • Depression
  • Neurotropin-3
  • Therapeutic implication

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Does neurotropin-3 have a therapeutic implication in major depression? / Pae, Chi Un; Marks, David M.; Han, Changsu; Patkar, Ashwin A.; Steffens, David.

In: International Journal of Neuroscience, Vol. 118, No. 11, 01.11.2008, p. 1515-1522.

Research output: Contribution to journalArticle

Pae, Chi Un ; Marks, David M. ; Han, Changsu ; Patkar, Ashwin A. ; Steffens, David. / Does neurotropin-3 have a therapeutic implication in major depression?. In: International Journal of Neuroscience. 2008 ; Vol. 118, No. 11. pp. 1515-1522.
@article{4b112a24482b4df3971cc9d517bd04d3,
title = "Does neurotropin-3 have a therapeutic implication in major depression?",
abstract = "Although several classes of antidepressants are used to treat major depression, there is an unmet need in real clinical practice because not all patients treated with an antidepressant fully recover from their functional impairment. Hence, the development of new antidepressants based on a novel therapeutic mechanism may help in the development of more effective and ideal antidepressive agents. There is emerging evidence suggesting that the etiopathogenesis of depression involves transmitters other than the major neurotransmitters such as serotonin, norepinephrine, and dopamine. Therefore, it has consistently been suggested that an alteration in neuroprotection and synaptic plasticity is associated with the pathogenesis and therapeutic mechanism of depression. Neurotropin-3 (NT3) is an interesting protein that regulates neuronal survival, synaptic plasticity, and neurotransmission. It is widely expressed in the hippocampus and facilitates hippocampal plasticity by regulating neurogenesis. It has been also reported that an infusion of NT3 increases the level of brain-derived neurotrophic factor (BDNF) mRNA expression in the cerebral cortex and produces BDNF-like effects that induce cortical tyrosine kinase B phosphorylation. BDNF has been consistently implicated in the pathogenesis of depression and the therapeutic mechanism of antidepressants. It has also been implicated in the treatment effect of mood stabilizers such as lithium. NT3 has demonstrated its possible antidepressant effect in a learned helpless animal model. Animal studies have shown that it also modulates the neurotransmitters, serotonin and noradrenaline, which are essential in the development and treatment of depression. Therefore, further studies on the therapeutic implications of NT3 for depression are warranted and are expected for the development of newer, effective antidepressants.",
keywords = "Depression, Neurotropin-3, Therapeutic implication",
author = "Pae, {Chi Un} and Marks, {David M.} and Changsu Han and Patkar, {Ashwin A.} and David Steffens",
year = "2008",
month = "11",
day = "1",
doi = "10.1080/00207450802174589",
language = "English",
volume = "118",
pages = "1515--1522",
journal = "International Journal of Neuroscience",
issn = "0020-7454",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Does neurotropin-3 have a therapeutic implication in major depression?

AU - Pae, Chi Un

AU - Marks, David M.

AU - Han, Changsu

AU - Patkar, Ashwin A.

AU - Steffens, David

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Although several classes of antidepressants are used to treat major depression, there is an unmet need in real clinical practice because not all patients treated with an antidepressant fully recover from their functional impairment. Hence, the development of new antidepressants based on a novel therapeutic mechanism may help in the development of more effective and ideal antidepressive agents. There is emerging evidence suggesting that the etiopathogenesis of depression involves transmitters other than the major neurotransmitters such as serotonin, norepinephrine, and dopamine. Therefore, it has consistently been suggested that an alteration in neuroprotection and synaptic plasticity is associated with the pathogenesis and therapeutic mechanism of depression. Neurotropin-3 (NT3) is an interesting protein that regulates neuronal survival, synaptic plasticity, and neurotransmission. It is widely expressed in the hippocampus and facilitates hippocampal plasticity by regulating neurogenesis. It has been also reported that an infusion of NT3 increases the level of brain-derived neurotrophic factor (BDNF) mRNA expression in the cerebral cortex and produces BDNF-like effects that induce cortical tyrosine kinase B phosphorylation. BDNF has been consistently implicated in the pathogenesis of depression and the therapeutic mechanism of antidepressants. It has also been implicated in the treatment effect of mood stabilizers such as lithium. NT3 has demonstrated its possible antidepressant effect in a learned helpless animal model. Animal studies have shown that it also modulates the neurotransmitters, serotonin and noradrenaline, which are essential in the development and treatment of depression. Therefore, further studies on the therapeutic implications of NT3 for depression are warranted and are expected for the development of newer, effective antidepressants.

AB - Although several classes of antidepressants are used to treat major depression, there is an unmet need in real clinical practice because not all patients treated with an antidepressant fully recover from their functional impairment. Hence, the development of new antidepressants based on a novel therapeutic mechanism may help in the development of more effective and ideal antidepressive agents. There is emerging evidence suggesting that the etiopathogenesis of depression involves transmitters other than the major neurotransmitters such as serotonin, norepinephrine, and dopamine. Therefore, it has consistently been suggested that an alteration in neuroprotection and synaptic plasticity is associated with the pathogenesis and therapeutic mechanism of depression. Neurotropin-3 (NT3) is an interesting protein that regulates neuronal survival, synaptic plasticity, and neurotransmission. It is widely expressed in the hippocampus and facilitates hippocampal plasticity by regulating neurogenesis. It has been also reported that an infusion of NT3 increases the level of brain-derived neurotrophic factor (BDNF) mRNA expression in the cerebral cortex and produces BDNF-like effects that induce cortical tyrosine kinase B phosphorylation. BDNF has been consistently implicated in the pathogenesis of depression and the therapeutic mechanism of antidepressants. It has also been implicated in the treatment effect of mood stabilizers such as lithium. NT3 has demonstrated its possible antidepressant effect in a learned helpless animal model. Animal studies have shown that it also modulates the neurotransmitters, serotonin and noradrenaline, which are essential in the development and treatment of depression. Therefore, further studies on the therapeutic implications of NT3 for depression are warranted and are expected for the development of newer, effective antidepressants.

KW - Depression

KW - Neurotropin-3

KW - Therapeutic implication

UR - http://www.scopus.com/inward/record.url?scp=53949087364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53949087364&partnerID=8YFLogxK

U2 - 10.1080/00207450802174589

DO - 10.1080/00207450802174589

M3 - Article

VL - 118

SP - 1515

EP - 1522

JO - International Journal of Neuroscience

JF - International Journal of Neuroscience

SN - 0020-7454

IS - 11

ER -